P-136 Establishment and characterization of amylase-producing lung adenocarcinoma cell line, IMEC-2

Yokouchi, Hideoki; Yamazaki, K.; Shigemura, Mayumi; Moriyama, Tomohiko; Konishi, Jiro; Takaoka, Kazuki; Nishimura, Mitsuyo

doi:10.1016/s0169-5002(05)80630-0

Cited by 3 publications

(8 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…They reported that electrophoretic separation of the amylase revealed fast-migration forms in serum 10 of 47 (21.3%) patients with malignant ovarian neoplasms. Unfortunately, they did not characterize the fast-migrating amylase isoenzyme forms [45], however, it is considered in the perspective of today think and as "sialyl salivary-type amylase" similar to our reports [25,28,29]. In the following, describe the research results that led to the identification of the amylase found in the sera with ovarian cancer.…”

supporting

confidence: 54%

“…The molecular mass of sialyl salivary-Cancer Treatment -Conventional and Innovative Approaches type amylase from myeloma was determined by immunoblotting to be approximately 60,000 Da, the same as normal salivary amylase [25]. Unfortunately, the equivalent experiment could not be repeated in this study, owing to the small serum sample sizes, but as the elution profiles in this report were the same as in previous reports [25][26][27][28], the molecular mass is assumed to be the same. However, the sialyl salivary-type amylases were well separated by Superose 12 HPLC analyses.…”

mentioning

confidence: 86%

“…In 2004, Shigemura et al [27] demonstrated, using cell culture and immunohistochemical techniques, that sialyl salivary-type amylase, together with normal salivary amylase (defined by electrophoretic characteristics), was produced by myeloma cells. In 2006, Yokouchi et al [28] also detected the same type of amylase in culture medium from the amylase-producing lung adenocarcinoma cell line IMEC-2. In 2008, the author reported that the characterization of sialyl salivary-type amylase associated with ovarian cancer using conserved sera that were obtained from a retrospective study of amylase zymograms [29].…”

Section: Review Of Related Literaturementioning

confidence: 96%

“…Unfortunately, neuramidase treatment and characterization of other properties were not performed in these studies. The author considers those amylases, from the findings of this and previous reports [25][26][27][28], to be most likely sialyl salivary-type. It seems likely that sialylated salivary-type amylase is directly produced together with normal salivary amylase by ovarian cancer cells, as in multiple mylelona cells [27] and lung cancer cells [28].…”

mentioning

confidence: 87%

“…Sialyl salivary-type amylase has been found in the sera of patients with lung cancer [24,28], pancreatic cancer [24], multiple myeloma [25], and ovarian cancer [29]. Therefore, it is expected that the sialyl salivary-type amylase will be found generally in patients with amylaseproducing tumors.…”

mentioning

confidence: 99%

See 4 more Smart Citations

Sialyl Salivary–Type Amylase Associated with Ovarian Cancer

Moriyama¹

2013

Cancer Treatment - Conventional and Innovative Approaches

View full text Add to dashboard Cite

The criteria were: a S3 to S2 ratio of over 1.0 and/or acidic fast-migrated sub-bands from S4 to S6. The sera were stored at-80ºC until required. A sample with a normal amylase isoenzyme electrophoretic pattern was used as control in the analyses of neuraminidase treatment, reaction with anti-salivary monoclonal antibody, and size-exclusion HPLC. 2.2. Measurement of total amylase activity Total serum amylase activity was measured on a Hitachi 7170 automated analyzer with G4-CNP as substrate (Toyobo, Osaka, Japan) at 37ºC. The reference interval of total serum amylase activity was from 40 to 160 U/L.

show abstract

supporting

confidence: 54%

mentioning

confidence: 86%

Section: Review Of Related Literaturementioning

confidence: 96%

mentioning

confidence: 87%

mentioning

confidence: 99%

See 3 more Smart Citations

Sialyl Salivary–Type Amylase Associated with Ovarian Cancer

Moriyama¹

2013

Cancer Treatment - Conventional and Innovative Approaches

View full text Add to dashboard Cite

show abstract

Establishment and characterization of a novel highly malignant lung cancer cell line ZX2021H derived from a metastatic lymph node lesion

et al. 2022

Thoracic Cancer

View full text Add to dashboard Cite

Background Lung cancer is a highly malignant tumor with a poor prognosis. The establishment of faithful ex vivo cell models is essential for investigating the metastatic mechanisms and developing new anticancer agents. In this study, we established and characterized a novel lung cancer cell line derived from metastatic lymph node tissue from a Chinese patient. Methods A primary culture of metastatic lymph node tissue from a patient with lung cancer was used to establish a cell line. The phenotypic characteristics of the cell line were characterized by colony‐formation, CCK8, and Transwell assays, and xenografting. The genetic characteristics were evaluated by chromosome analysis, short tandem repeat (STR) profiling, and quantitative real time‐polymerase chain reaction (qRT‐PCR). Results A novel lung cancer cell line, named ZX2021H, was successfully established from a metastatic lymph node lesion from a lung cancer patient. The cell line exhibited high capacities for proliferation and invasion, as validated by its phenotypic and genetic characteristics. This cell line had a unique STR profile and karyotype analysis revealed numerical and structural chromosome abnormalities. The growth rate of in vivo xenografted tumors established using ZX2021H cells was higher than that using H1299 cells. The cell stemness‐related gene SOX2 was overexpressed in ZX2021 compared with H1299 cells, as determined by qRT‐PCR. Conclusion We successfully established a novel, highly malignant lung cancer cell line, ZX2021H, derived from metastatic lymph node tissue from a Chinese lung cancer patient. This cell line may provide an ideal cell model for further studies of the molecular mechanisms underlying lung cancer metastasis and for the development of new anticancer agents.

show abstract

Amylase-Producing Lung Cancer with a Positive Epidermal Growth Factor Receptor Mutation Treated With Gefitinib: A Case Report

Minami

2014

World J Oncol

View full text Add to dashboard Cite

A 60-year-old woman was diagnosed with metastatic pulmonary adenocarcinoma (c-stage IV) with an L858R point mutation in the gene encoding epidermal growth factor receptor (EGFR). Serum amylase levels were elevated (1,531 IU/L) with the salivary-type enzyme dominating. First-line chemotherapy using carboplatin plus paclitaxel reduced serum amylase levels, although second-line gefitinib eventually failed to control tumor growth and hyperamylasemia after 4.5 months of treatment. The cancer cells harbored a positive EGFR mutation and secreted amylase. The number of amylase-producing cancer cells and the immunochemical staining intensity for amylase were significantly reduced after gefitinib treatment. This was a rare case of a lung cancer that expressed amylase and harbored a positive EGFR mutation.

show abstract

P-136 Establishment and characterization of amylase-producing lung adenocarcinoma cell line, IMEC-2

Cited by 3 publications

References 0 publications

Sialyl Salivary–Type Amylase Associated with Ovarian Cancer

Sialyl Salivary–Type Amylase Associated with Ovarian Cancer

Establishment and characterization of a novel highly malignant lung cancer cell line ZX2021H derived from a metastatic lymph node lesion

Amylase-Producing Lung Cancer with a Positive Epidermal Growth Factor Receptor Mutation Treated With Gefitinib: A Case Report

Contact Info

Product

Resources

About